Abstract | OBJECTIVE: The chemokine receptor CXCR4 and its ligand CXCL12 are involved in the progression and dissemination of a diverse number of solid and hematological malignancies. Binding CXCL12 to CXCR4 activates a variety of intracellular signal transduction pathways that regulate cell chemotaxis, adhesion, survival, proliferation, and apoptosis. MATERIALS AND METHODS: RESULTS: CONCLUSIONS:
|
Authors | Katia Beider, Michal Begin, Michal Abraham, Hanna Wald, Ido D Weiss, Ori Wald, Eli Pikarsky, Evelyne Zeira, Orly Eizenberg, Eithan Galun, Izhar Hardan, Dan Engelhard, Arnon Nagler, Amnon Peled |
Journal | Experimental hematology
(Exp Hematol)
Vol. 39
Issue 3
Pg. 282-92
(Mar 2011)
ISSN: 1873-2399 [Electronic] Netherlands |
PMID | 21138752
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- 4-fluorobenzoyl-TN-14003
- Anti-HIV Agents
- Antineoplastic Agents
- Benzylamines
- CXCL12 protein, human
- CXCR4 protein, human
- Chemokine CXCL12
- Cyclams
- Heterocyclic Compounds
- Peptides
- Receptors, CXCR4
- plerixafor
|
Topics |
- Animals
- Anti-HIV Agents
(pharmacology)
- Antineoplastic Agents
- Apoptosis
(drug effects)
- Benzylamines
- Chemokine CXCL12
(metabolism)
- Cyclams
- HL-60 Cells
- Heterocyclic Compounds
(pharmacology)
- Humans
- Jurkat Cells
- Leukemia, Myeloid, Acute
(drug therapy, metabolism)
- Mice
- Mice, SCID
- Multiple Myeloma
(drug therapy, metabolism)
- Neoplasm Transplantation
- Peptides
(pharmacology)
- Receptors, CXCR4
(antagonists & inhibitors, metabolism)
|